A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
NCT03948581 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102
Last updated 2022-07-29
Summary
The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
Conditions
- Healthy Volunteers
Interventions
- DRUG
-
Vedolizumab SC
Vedolizumab SC liquid.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Takeda
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-02-21
- Primary Completion
- 2018-08-14
- Completion
- 2018-09-21
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers
NCT02458209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
NCT01385566 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
NCT00397943 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
NCT06212804 ·Status: COMPLETED ·Phase: PHASE1
-
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
NCT04845191 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)
NCT02180295 ·Status: WITHDRAWN ·Phase: PHASE3
-
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
NCT05710783 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
NCT06674941 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Yellow Fever Inactivated Vaccine
NCT00995865 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination
NCT01963338 ·Status: COMPLETED ·Phase: NA
-
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
NCT01765426 ·Status: COMPLETED ·Phase: PHASE1
-
LT Vaccine Patch Self-Administration Study
NCT00565461 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
NCT05815498 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
NCT03239873 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers
NCT00749034 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
NCT00985153 ·Status: COMPLETED ·Phase: PHASE3
-
Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers
NCT05398562 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
NCT01391546 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
NCT02538341 ·Status: COMPLETED ·Phase: PHASE2
-
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
NCT05331885 ·Status: TERMINATED ·Phase: PHASE3
-
Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy
NCT02408159 ·Status: TERMINATED ·Phase: PHASE4
-
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
NCT00561080 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®
NCT02511587 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
NCT04420221 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
NCT01527383 ·Status: COMPLETED ·Phase: PHASE2